» Articles » PMID: 39594735

Advances in the Management of Lung Cancer Brain Metastases

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Nov 27
PMID 39594735
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer, both non-small cell and small cell, harbors a high propensity for spreading to the central nervous system. Radiation therapy remains the backbone of the management of brain metastases. Recent advances in stereotactic radiosurgery have expanded its indications and ongoing studies seek to elucidate optimal fractionation and coordination with systemic therapies, especially targeted inhibitors with intracranial efficacy. Efforts in whole-brain radiotherapy aim to preserve neurocognition and to investigate the need for prophylactic cranial irradiation. As novel combinatorial strategies are tested and prognostic/predictive biomarkers are identified and tested, the management of brain metastases in lung cancer will become increasingly personalized to optimally balance intracranial efficacy with preserving neurocognitive function and patient values.

References
1.
Limon D, McSherry F, Herndon J, Sampson J, Fecci P, Adamson J . Single fraction stereotactic radiosurgery for multiple brain metastases. Adv Radiat Oncol. 2017; 2(4):555-563. PMC: 5707418. DOI: 10.1016/j.adro.2017.09.002. View

2.
Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

3.
Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C . A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncol. 2023; 19(3):465-475. DOI: 10.1016/j.jtho.2023.10.014. View

4.
Hou X, Li M, Wu G, Feng W, Su J, Jiang H . Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study. JAMA Netw Open. 2023; 6(2):e2255050. PMC: 9909498. DOI: 10.1001/jamanetworkopen.2022.55050. View

5.
Lehrer E, Khosla A, Ozair A, Gurewitz J, Bernstein K, Kondziolka D . Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients. J Neurooncol. 2023; 165(1):63-77. DOI: 10.1007/s11060-023-04413-4. View